<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680134</url>
  </required_header>
  <id_info>
    <org_study_id>AN2690-ONYC-203</org_study_id>
    <secondary_id>C3371007</secondary_id>
    <nct_id>NCT00680134</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis</brief_title>
  <official_title>An Open Label, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 1% And 5% Solutions For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and efficacy of 1% and 5% AN2690
      solutions in the treatment of distal, subungual onychomycosis of the great toenail.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first group of 30 protocol-qualified subjects will be assigned to Treatment Group 1 and
      given 1% AN2690 Solution. The second group of 30 protocol-qualified subjects will be assigned
      to Treatment Group 2 and given 5% AN2690 Solution.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2006</start_date>
  <completion_date type="Actual">August 31, 2007</completion_date>
  <primary_completion_date type="Actual">August 31, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete or partial clinical evidence of great toenail clearance or at least 2 mm of fungal clear linear great toenail growth plus a negative fungal culture from the treatment targeted toenail at the End-of-treatment (Day 180)</measure>
    <time_frame>Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluations of mycological response, changes from baseline linear toenail growth, proportion of subjects who are successful &quot;Complete Responders&quot;</measure>
    <time_frame>Day 180</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Group/Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2690 1% Solution (30 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group/Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN2690 5% Solution (30 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 1% Solution, once daily for 180 days</description>
    <arm_group_label>Group/Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days</description>
    <arm_group_label>Group/Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Witnessed, signed informed consent approved by Institutional Review Board/Ethics
             Committee

          -  A signed Health Insurance Portability and Accountability Act (HIPAA) authorization
             form which permits the use and disclosure of subject's individually identifiable
             health information for those enrolled in the United States of America

          -  Male or female subjects of any race 18 -65 years of age

          -  Subjects with a diagnosis of onychomycosis of at least one great toenail and with a
             positive KOH wet mount and a positive fungal culture for dermatophyte species

          -  Onychomycosis involving 20-60% of the affected great toenail as determined at baseline
             (Day1) by visual inspection after the nail has been trimmed

          -  The combined thickness of the distal nail plate and the associated hyperkeratotic nail
             bed &lt;3 mm

          -  Affected great toenail to be treated is capable of re-growth as documented by history
             or recent observation of at least 2 mm of growth

        Exclusion Criteria:

          -  Females of childbearing potential not using a highly effective method of birth control
             (e.g. implants, injectables, combined oral contraceptives, some intrauterine
             contraceptive devices) during the study

          -  Subjects unwilling to refrain from the use of nail cosmetics such as clear and or
             colored nail lacquers from the screening visit until the end of the study

          -  Subjects with chronic moccasin type of T. pedis

          -  Subjects with a history of having failed any previous topical antifungal therapy for
             their onychomycosis

          -  Diabetes mellitus requiring treatment other than diet and exercise

          -  Subjects that have not undergone the specified washout period(s) for the following
             topical preparations or subjects who require the concurrent use of any of the
             following topical medications:

               1. Topical antifungal applied to toenails (does not include antifungals for
                  treatment of T. pedis): 12 weeks

               2. Anti-inflammatories, corticosteroids, topical immunomodulators (in the treatment
                  area): 2 weeks

          -  Subjects that have not undergone the specified washout period(s) for the following
             systemic medications or subjects who require the concurrent use of any of the
             following systemic medications:

               1. Corticosteroids (including intramuscular injections): 2 weeks

               2. Antifungals for treatment of onychomycosis or any systemic antifungal with known
                  activity against dermatophyte species: 24 weeks

               3. Systemic immunomodulators: 4 weeks

          -  Treatment of any type for cancer within the last 6 months

          -  History of any significant internal disease

          -  Subjects with a medical history of current or past psoriasis of the skin and/or nails

          -  Concurrent lichen planus

          -  Subjects who are known to be allergic to any of the test product(s) or any components
             in the test product(s) or history of hypersensitivity or allergic reactions to any of
             the study preparations as described in the Investigator's Brochure

          -  Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary
             disorders, onychogryphosis, trauma to the nail(s) to be treated

          -  AIDS or AIDS related complex

          -  History of street drug or alcohol abuse

          -  Any subject not able to meet the study attendance requirements

          -  Subjects who have participated in any other trial of an investigational drug or device
             within 60 days prior to enrollment or participation in a research study concurrent
             with this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, PA &amp; San Antonio Podiatry Associates, PC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Fungal Nail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tavaborole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

